Johnson & Johnson Stock Could Be a Defensive Play for the Years Ahead

Johnson & Johnson just posted a quarter that sent shares sliding despite a headline beat, yet analysts keep piling into the bull camp with price targets well above current levels. Here is what the numbers actually say about whether this healthcare giant earns its premium valuation.